-
We will be discussing AD plasma biomarkers in participants with Down syndrome. Many of our discussions in the past few weeks have centered around how comorbidities and enhanced risk may affect the relationship between biomarker and disease. This week, we will take a closer look at a clinical population that has a genetically determined high risk of AD and […]

